Introduction
• The efficacy of an inhaled drug depends on the propensity for drug particles to deposit throughout the lungs. Airway deposition is affected by several, often interrelated factors, including the intrinsic inhaler properties, drug formulation and patient characteristics.
• In vitro particle size profiles of emitted particles correlate with in vivo lung deposition. Particles > 5 µm in diameter are prone to being deposited in the mouth or throat, where they do not exert therapeutic effects and may increase the risk of local side effects. Fine particles (< 5 µm) are associated with deposition throughout the airways. The proportion of an emitted aerosolized drug dose that contains fine particles is referred to as the fine particle fraction (FPF).
• The inhaled corticosteroid (ICS) fluticasone propionate (FP) and long-acting β 2 -agonist (LABA) formoterol fumarate (FORM) have been combined in a single, hydrofluoroalkane (HFA)-based, aerosol inhaler (FP/FORM; flutiform ® ). FP/FORM is approved for maintenance treatment of asthma at twice-daily doses of 100/10 µg, 250/10 µg (patients aged ≥ 12 years) and 500/20 µg (patients aged ≥ 18 years only) when an ICS/LABA therapy is appropriate.
• In this study, the in vitro FPF profile of FP/FORM was compared with fluticasone propionate/salmeterol (FP/SAL) and budesonide/ formoterol (BUD/FORM) dry powder inhalers (DPIs). The beclometasone dipropionate/formoterol (BDP/FORM) pressurized metereddose inhaler (pMDI) aerosol was included as a benchmark comparator.
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Fast facts
• The efficacy of inhaled products is affected by the degree, and potentially the site, of drug particle deposition in the lungs. Airway deposition is affected by several, often interrelated factors, including patient characteristics, the intrinsic properties of the inhaler and drug formulation. Deposition correlates with the fine particle fraction (FPF; proportion of dose containing particles < 5 µm in aerodynamic diameter). 
Results
• FP/FORM produced a high and consistent FPF of ~ 40% for both the ICS and the LABA components at each flow rate (Figure 1 ). • This in vitro study compared the aerodynamic particle size distribution (APSD) profiles of FP/FORM, FP/SAL, BUD/FORM and BDP/FORM, at drug strengths which can be used to deliver similar treatment doses (via 1 or 2 actuations at a single dose strength for each inhaler).
-APSD profiles were assessed using an 8-stage Andersen Cascade Impactor at inhalation flow rates of 28.3 and 60.0 L/min.
• The FPF was calculated as a percentage of the labelled dose for the ICS and for the LABA component. Ratios were calculated between FPFs at both flow rates (FPF 60.0/28.3 L/min); equivalence was concluded if the 90% confidence interval (CI) was contained in the 0.85-1.18 (± 15%) acceptance interval.
Study design
• In vitro, FP/FORM emits a high and consistent FPF (approximately 40%) at 28.3 and 60.0 L/min that was greater than those of FP/ SAL and BUD/FORM. The FPF of FP/FORM was less affected by changes in flow rate than the other products tested.
• A patient's inhalation flow rate is not constant during an inhalation manoeuvre and may vary from breath to breath (and thus from dose to dose), and from patient to patient; therefore, an ICS/LABA with a consistent FPF that is relatively flow rate independent might facilitate more uniform dosing in the lungs.
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Presentation
Pressurised inhalation suspension, in a pressurised metered dose inhaler (pMDI), containing fluticasone propionate and formoterol fumarate dihydrate at strengths of 50 µg/5 µg, 125 µg/5 µg or 250 µg/10 µg per actuation.
Indications
Regular treatment of asthma where the use of a combination product (inhaled corticosteroid and long-acting β 2 -agonist) is appropriate. For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β 2 -agonist (SABA), or for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β 2 -agonist (LABA). flutiform 50 µg/5 µg and 125 µg/5 µg per actuation are indicated for use in adults and adolescents 12 years and above. flutiform 250 µg/10 µg per actuation is only indicated for use in adults. Patients should be assessed regularly and once asthma is controlled, treatment should be reviewed and stepped down to the lowest effective dose, or an ICS alone. It is extremely important to regularly review patients as their treatment is stepped down. ICSs alone are first line treatment for most patients. flutiform is not intended for initial treatment of mild asthma. For patients with severe asthma the ICS therapy should be established before prescribing a fixed-dose combination product.
Dosage and administration
Patients on flutiform must not use an additional LABA. An inhaled SABA should be taken for immediate relief of asthma symptoms arising between doses. The AeroChamber Plus® spacer device is recommended in patients who find it difficult to use inhalers; re-titration should always follow the introduction of a spacer device. Patients should be advised to contact their prescriber when the flutiform dose counter is getting near zero.
Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Precautions and warnings flutiform should not be used for the first treatment of asthma, to treat acute asthma symptoms or for prophylaxis of exercise-induced asthma. It should not be initiated during an exacerbation, during significantly worsening or acutely deteriorating asthma, and should not be stopped abruptly. Patients should use their flutiform maintenance treatment as prescribed, even when asymptomatic. If a patient experiences serious asthma-related adverse events or exacerbations, they should continue treatment but also seek medical advice. Patients should be reviewed as soon as possible if there is any indication of deteriorating asthma control. In the case of sudden and progressive deterioration, which is potentially life-threatening, an urgent medical assessment should be carried out. Use with caution in patients with: pulmonary tuberculosis; quiescent tuberculosis; fungal, viral or other infections of the airway; thyrotoxicosis; pheochromocytoma; diabetes mellitus (consider additional blood sugar controls); uncorrected hypokalaemia; predisposition to low levels of serum potassium; impaired adrenal function (monitor HPA axis function regularly); hypertrophic obstructive cardiomyopathy; idiopathic subvalvular aortic stenosis; severe hypertension; aneurysm or other severe cardiovascular disorders. There is risk of potentially serious hypokalaemia with high doses of β 2 -agonists or concomitant treatment with β 2 -agonists and drugs that can induce or potentiate a hypokalaemic effect. Particular caution is recommended in unstable or acute severe asthma and other conditions when the likelihood for hypokalaemia adverse effects is increased. Monitoring of serum potassium levels is recommended during these circumstances. Formoterol may induce prolongation of the QTc interval. Caution must be observed when treating patients with existing prolongation of QTc interval. flutiform should be discontinued immediately if there is evidence of paradoxical bronchospasm.
Systemic effects with an ICS may occur, particularly at high doses for prolonged periods or when combined with potent CYP3A4 inhibitors, but are less likely than with oral corticosteroids. Use of a spacer device may also cause an increased systemic exposure. Increased exposure can be expected in patients with severe hepatic impairment.
Prolonged treatment with high doses of corticosteroids may result in adrenal suppression and acute adrenal crisis, particularly in adolescents and children or potentially as a result of trauma, surgery, infection or rapid dose reduction.
Patients should be advised that flutiform contains a small amount of ethanol; however, this negligible amount does not pose a risk to patients. flutiform is not recommended in children under 12 years of age.
